Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900190 | 0.88 | KCNJ1 (0.62) | KCNJ1KCNH2 | |
| SCHEMBL13028050 | 0.85 | KCNJ1 (0.53) | KCNJ1KCNH2 | |
| SCHEMBL2895014 | 0.76 | KCNJ1 (0.69) | KCNJ1KCNH2 | |
| SCHEMBL10234057 | 0.73 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL13028040 | 0.73 | KCNJ1 (0.56) | KCNJ1KCNH2 | |
| SCHEMBL10233884 | 0.71 | KCNJ1 (0.75) | KCNJ1KCNH2 | |
| SCHEMBL13027852 | 0.69 | KCNJ1 (0.69) | KCNJ1KCNH2 | |
| SCHEMBL2898390 | 0.69 | KCNJ1 (0.69) | KCNJ1KCNH2 | |
| SCHEMBL2898394 | 0.69 | KCNJ1 (0.69) | KCNJ1KCNH2 | |
| SCHEMBL2901460 | 0.69 | KCNJ1 (0.69) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.